PLK1 and hematologic disorder: Onvansertib is a novel oral, highly selective adenosine triphosphate (ATP) competitive Plk1 inhibitor that has demonstrated anti-tumorigenic activity in multiple types of solid tumors and hematologic malignancies, including AML, medulloblastoma, ovarian cancer, breast cancer, and colon cancer (Wang et al., 2022; Affatato et al., 2020; Stebbing and Bullock, 2024a).